C4 Therapeutics Appoints Thomas E. Needham, Jr., MBA As Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--C4 Therapeutics today announced the appointment of Thomas E. Needham, Jr., MBA, to the position of Chief Business Officer. Mr. Needham joins with over 20 years of experience in venture capital, business development, corporate strategy and executive management responsibilities in public and private biotechnology companies. In this new role, Mr. Needham will lead C4 Therapeutics' corporate and business development, finance, legal and corporate communications functions.

Suggested Articles

Adimab spinout Adagio Therapeutics raised $50 million to develop antibodies that target SARS-CoV-2 and other coronaviruses.

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.